More tools

Kodiak Sciences Inc.

KOD

Kodiak Sciences Inc.

2.56

-0.24

(-8.73%)

Today

As of 4:00 PM Eastern

Pre Market

Options AI - All Directions

Apr 17 Expected Move

See where the options market thinks KOD will move from here.

Trade the Expected Move

Kodiak Sciences Inc.

Market Cap: 134.72 million

PE Ratio: -0.76

Volume: 419.61 thousand

Sector: Healthcare

Industry: Biotechnology

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.